1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Forest to acquire Clinical Data Inc to add antidepressant Viibryd to portfolio

 
• By Nancy Faigen

Forest Laboratories has entered into a definitive merger agreement to acquire Clinical Data Inc for $30 per share in cash, plus a contingent value (CVR) right worth up to $6 per share based on sales performance milestones of Clinical Data's first-of-its-kind antidepressant Viibryd (vilazodone HCl), which gained FDA approval on 24 January. The CVR is meant to allow the acquiring company to mitigate long-term risk.

Forest Laboratories has entered into a definitive merger agreement to acquire Clinical Data Inc for $30 per share in cash, plus a contingent value (CVR) right worth up to $6 per share based on sales performance milestones of Clinical Data's first-of-its-kind antidepressant Viibryd (vilazodone HCl), which gained FDA approval on 24 January. The CVR is meant to allow the acquiring company to mitigate long-term risk.

Viibryd is expected to be launched in the US in the second half of this year, according to Forest's management,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapeutic Category

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.